Status:
RECRUITING
Age Differences in the Effects of Cannabis on Simulated Driving
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Cannabis
Eligibility:
All Genders
19-45 years
Phase:
NA
Brief Summary
Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor ...
Detailed Description
Epidemiological studies have established that the use of cannabis can increase the risk of a motor vehicle collision. A number of variables can influence the effects of cannabis on driving. For exampl...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- 19-25 or 35-45 years of age;
- Use of smoked cannabis at least once in the past 6 months.
- Use of smoked or vaped cannabis primarily for recreational purposes on up to 1 day per week or on at least 6 days per week in the past 3 months;
- Holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;
- Willing to abstain from using alcohol for 24 hours and cannabis for 72 hours prior to Practice and Test Sessions;
- Willing to abstain from all other drugs not prescribed for medical purposes for 48 hours prior to Practice and Test Sessions;
- Resides within Toronto (study site) or can reside with friends/family in Toronto after a Test Session; this area may be extended to the Greater Toronto area if recruitment challenges arise;
- Participant willing to use appropriate contraception until their participation in the study is completed;
- Provides written and informed consent.
- Exclusion Criteria
- Use of cannabis primarily for therapeutic purposes, or equally for therapeutic and recreational purposes;
- Diagnosis of medical condition that contraindicates use of cannabis determined by self-report as judged by the Principal Investigator and a study physician; this includes a history of hypersensitivity to cannabinoids smoke, respiratory disease and/or severe cardiovascular, cerebrovascular, renal or liver disease, and bleeding disorders. Smoking cannabis is not recommended for individuals with respiratory diseases, and they will be excluded;
- Diagnosis of psychiatric condition that contraindicates use of cannabis determined by self-report or SCID-5;
- Participants of childbearing potential: Pregnancy (point-of-care test) or breastfeeding;
- Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder;
- Is a regular user of medications that affect brain function (based on self-report); this includes concomitant therapy with sedative-hypnotics or other psychoactive drugs
- Use of anti-hypertensives;
- First-degree relative diagnosed with schizophrenia or another psychotic disorder.
- Participation in a past driving study at CAMH (to limit practice effects).
- Participation in a clinical study concurrent with their participation in this study.
Exclusion
Key Trial Info
Start Date :
March 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04325958
Start Date
March 27 2024
End Date
March 1 2027
Last Update
April 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5S 2S1